Healthy
Conditions
Keywords
Bioequivalence, Nabumetone, Healthy subjects
Brief summary
The purpose of this study is to evaluate the relative bioavailability of two formulations of nabumetone tablets to establish their average bioequivalence
Detailed description
Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design. Official Title: Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers Further study details as provided by Actavis Elizabeth LLC: Primary Outcome Measures: Rate and Extend of Absorption
Interventions
A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
Sponsors
Actavis Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Healthy subjects at least 18 years of age. 2. Availability of the subject for the entire study period and willingness to provide written informed consent after being informed of the nature of the study. 3. Body mass index (BMI) between 18 and 30 kg/m2 (calculated using the BMI Calculator on the Centers for Disease Control and Prevention \[CDC\] website available at http://www.cdc.gov/nccdphp/dnpa/bmi/index.htm, last accessed 19 Mar 07) and a weight of at least 110 pounds. 4. Good health as determined by a lack of clinically significant abnormalities in health assessments performed at Screening, as judged by the physician. 5. Females were required to use a medically acceptable method of hormonal contraception or abstinence throughout the entire study period and for one week after the study is completed
Exclusion criteria
1. Hypersensitivity to nabumetone (Nabumetone) or related compounds. 2. Conditions that affected the absorption, metabolism, or passage of drugs out of the body (eg, sprue, celiac disease, Crohn's disease, colitis, liver, kidney, or thyroid conditions). 3. Recent history (within 1 year) of mental illness, drug addiction, drug abuse, or alcoholism. 4. A hematocrit value of ≤ 33.0% for females and ≤ 37.0% for males. 5. Donation of \> 500 mL of blood in the past 8 weeks prior to study drug dosing or difficulty in donating blood. 6. Receipt of an investigational drug within the 4 weeks prior to study drug dosing. 7. Currently taking any systemic prescription medications, excluding hormone contraceptives, within the 7 days prior to study dosing or over-the-counter medication within 3 days of study dosing. This prohibition did not include vitamins or herbal preparations taken as nutritional supplements for non-therapeutic indications, as judged by the attending physician. Any nonprescription medication consumption reported was to be reviewed by the investigator prior to dosing. At the discretion of the investigator, these volunteers could be enrolled if the medication was not anticipated to alter study integrity. 8. Regular smoking of more than 5 cigarettes weekly or the regular daily use of nicotinecontaining products beginning 3 months before study drug administration through the final evaluation. 9. Female subjects who were lactating or had a positive pregnancy test at Screening and prior to each of the treatment periods. 10. Alcohol, grapefruit beverages or foods, caffeine, or xanthine beverages or foods beginning 48 hours before each study drug administration through the last pharmacokinetic (PK) sample of each treatment period. Such restricted items included coffee, tea, iced tea, Coke®, Pepsi®, Mountain Dew®, chocolate, brownies, etc. 11. Regular use of any drugs known to induce or inhibit hepatic drug metabolism (examples include barbiturates, carbamazepine, rifampin, phenylhydantoins, phenothiazines, cimetidine, omeprazole, macrolides, imidazoles, fluoroquinolones) within 30 days prior to study drug administration. 12. Positive test results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), and hepatitis C antibody at Screening. 13. Positive test results for drugs of abuse or pregnancy at Screening and prior to each study drug dosing period. Any deviation from these inclusion and
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate and Extend of Absorption | 120 hours |
Countries
United States
Outcome results
None listed